secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001437749-25-033362
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart signs exclusive license with Dynavax for oral COVID-19 vaccine; $25M upfront, $5M equity investment
--------------------------------------------------------------------------------

- Dynavax pays $25M upfront license fee and $5M equity (11.1M shares at $0.45/share) for worldwide rights to Vaxart's oral COVID-19 vaccine.
- Vaxart retains responsibility to complete ongoing Phase 2b trial (enrolled ~5,400; topline data expected late 2026) and EOP2 meeting.
- After Phase 2b data, Dynavax can elect to assume development for $50M additional payment; otherwise agreement terminates.
- If Dynavax continues, Vaxart eligible for up to $195M regulatory milestones, $425M sales milestones, and low-to-mid teens royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925033362/0001437749-25-033362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925033362/vxrt20251104_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer